anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention generally relates to a remote medical device for monitoring health of patient and communicating patient's health status to physician, and further relates to its design and methods of use there off. The health monitoring device with sensors for the diagnosis and measurement of physical health parameters. The portable electronic device has the inbuilt software storing the required data. The offsite device stores the information first and then it is transferred to the cloud. The physician checks the data updated regularly to know about the condition of the patient. The physician can interact with patient and re access the parameter during video or audio conversations with use. Data Analysis of the data thus captured is used for preparing an analysis report based on the web application analysis tools and sending of the detailed images and analysis report along with expert opinion for action required. The present invention generally relates to a remote medical device for monitoring health of patient and communicating patient's health status to physician, and further relates to its design and methods of use there off. The health monitoring device with sensors for the diagnosis and measurement of physical health parameters. The portable electronic device has the inbuilt software storing the required data. The offsite device stores the information first and then it is transferred to the cloud. The physician checks the data updated regularly to know about the condition of the patient. The physician can interact with patient and re access the parameter during video or audio conversations with use. Data Analysis of the data thus captured is used for preparing an analysis report based on the web application analysis tools and sending of the detailed images and analysis report along with expert opinion for action required.
Wash affected areas gently with a non-medicated soap. Apply a thin film of adapalene gel to the entire face and any other affected areas of the skin once daily in the evening. Avoid application to the areas of skin around eyes, lips, and mucous membranes. A mild transitory sensation of warmth or slight stinging may occur shortly after the application of adapalene gel. Instruct patients to minimize sun exposure and to use moisturizers for relief of dry skin or irritation.

If therapeutic results are not noticed after 12 weeks of treatment, therapy should be re-evaluated.

For topical use only. Not for ophthalmic, oral or intravaginal use.
NEW MATERIAL:A p-(3,3,3-trifluoropropyl)benzyl derivative of formulaI(X is chloro, cyano, carboxyl). EXAMPLE:p-(3,3,3-Trifluoropropyl)benzyl chloride. USE:Organic synthetic intermediate, anti-inflammatory, edema inhibitor, where the latter two compounds have a carboxyl as the X in compoundI. PREPARATION:(3,3,3-Trifluoropropyl)benzene of formula II is made to react with paraformaldehyde and hydrogen chloride in the presence of zinc chloride to give a compound of formula III, which is purified to give a compound of formulaIwhere X is Cl. The chlorine group of the compound is converted into a cyano group to form another compound of formulaIwhere X is CN. Then the product is hydrolyzed to give the third compound of formulaIwhere X ia carboxyl.
The liver is the most frequent and often the only site of distant disease in colorectal cancer and, of all treatment protocols currently in use, resection is the most likely to result in long-term cure. Within the liver, tumour proximity to major vasculature and biliary structures poses a resection challenge, requiring a balance of achieving negative margins while preserving adequate vascular circulation and biliary drainage. The focus on parenchymal sparing resections are important but just as important may be the 'biological' behaviour of the tumour. In colorectal liver metastases (CRLM), biomarkers such as the Kirsten rat sarcoma oncogene homologue (KRAS) gene and histological growth patterns (HGPs) further improve the prognostication after resection. However, to date, the association between the KRAS status and HGPs in CRLM and their impact on resection margins around major vasculature or biliary structures in terms of overall survival and recurrence rates are unclear. The aim of this review was to explore the available evidence for the association between KRAS and HGPs in CRLM and attempt to define their impact on resection margins near major structures.
Narcolepsy is a lifelong sleep disorder disease, mainly occurs in the 15\~30 year old youth. The incidence rate in different country population is different, which is 0.04% in China. Because of its low incidence rate, and the lack of clinicians' knowledge, it is easy to cause missed diagnosis and misdiagnosis. The decrease of cerebrospinal fluid orexin-A level, positive HLA-DQB1 \* 0602 and MSLT all have directive significance for the diagnosis of narcolepsy, but patients with other diseases and healthy people can also show positive indicators. These false positives may lead to wrong judgments. By comparing the differences of orexin-A, HLA gene, PSG, MSLT and other parameters in the evaluation of narcolepsy patients, investigators could find out the relatively high value indicators in the diagnosis of narcolepsy, which is helpful to guide the clinical discovery, diagnosis and treatment of narcolepsy.
The present invention relates to a traditional Chinese medicine for treating mental disorder, namely, a pill for tranquilizing and curing mania and a preparing method thereof. The pill for tranquilizing and curing mania is characterized in that the pill for tranquilizing and curing mania is prepared from traditional Chinese medicines as main materials compounded with small doses of western medicines, and the formulation is as follows: baical skullcap root, bezoar, gentian root, rhubarb, raw keel, raw oyster shell, red peony root, bupleurum root, lightyellow sophora root, clozapine and carbamazepine. The preparing method comprises: grinding the traditional Chinese medicines and the western medicines; sieving and uniformly mixing the powder; adding refined honey to the powder; preparing the mixture into honeyed pills or filling the mixture in capsules. The pill for tranquilizing and curing mania has the efficiency of fever reduction, pathogenic fire purging and tranquilization. When the pill for tranquilizing and curing mania is used for clinically treating manic-depressive psychosis(manic-depressive type) and positive schizophrenia, the cure rate reaches 86%, and the effective rate reaches above 94%. The pill for tranquilizing and curing mania has the characteristics of reliable therapeutic effect, little toxic or side effect and short treatment cycle.
In this percutaneous absorption agent, an ionic liquid is finely dispersed in an oil phase, the ionic liquid including a hydrophilic peptide drug, choline, and carboxylate ions obtained by dissociation of hydrogen ions from carboxy groups of a fatty acid. The average particle diameter of the ionic liquid finely dispersed in the oil phase may be 1-100 nm. The centers of particles of the ionic liquid finely dispersed in the oil phase may comprise the hydrophilic peptide drug and one or more selected from the group consisting of choline propionate, choline lactate, and choline formate. The hydrophilic peptide drug may be insulin. The fatty acid may be oleic acid or linoleic acid. The percutaneous absorption agent may further include sorbitan monolaurate in the oil phase.
The invention discloses a Chinese herbal plaster for treating gastric ulcer, which is a medical preparation derived from the plant and which is composed of a mucilage layer, a protective layer and a backing membrane layer. The herbs in the mucilage layer consist of radix aconiti preparata, fried rhizome of atractylodes macrocephala, alpinia officinarum hance, cyperus tuber powder, fried bitter orange, charred dried ginger and charred radix et rhizome rhei. The effective components which are extracted by the process of water extracting-alcohol precipitating, together with the pressure sensitive adhesive and the transdermal enhancer in proportion is made into a mucilage pulp containing medicine. The mucilage coating which is on the backing membrane layer is first compounded with the protective layer, then is disinfected and cut into finished product. Compared with the oral medicament form, the invention is free of the enterohepatic first pass effect, disaffected by degradation in gastrointestinal tract, of high bioavailability and innocuous. The curative effect of the invention to the gastric ulcer patients is obvious.
Current standard of care which is to advise families of infants diagnosed with peanut allergy to introduce tree nuts individually via a standardized, graded and cautious home introduction protocol. Day 1: smear of nut paste to the inside of lip; Day 2: 1/8 teaspoon; Day 3: 1/4 teaspoon; Day 4: 1/2 teaspoon; Day 5: 1 teaspoon. Repeat process with each individual tree nut.
INTRODUCTION: Littoral cell angioma (LCA) is a new subtype of vascular tumor, which has been reported infrequently worldwide. It is associated with visceral malignancies and other immunologic conditions.
CLINICAL CASE: We present a case of a 70-year-old Caucasian male with a 6-year history of myelodysplastic syndrome, which was investigated for splenomegaly and pancytopenia. Radiological and histopathological examinations revealed an LCA and an open splenectomy were performed. The patient had an uneventful post-operative recovery.
CONCLUSION: LCA is a rare tumor, with atypical presentation often associated with other malignancies or immunologic conditions. Diagnosis is challenging, and so far, splenectomy is the gold standard treatment.
Climate change is having a dramatic effect on the environment, with rising global temperatures and more frequent extreme climatic events, such as heatwaves, that can hamper organisms' biological functions. Although it is clear that sudden and extreme temperatures can damage reproductive processes, there is limited understanding of the effects of heatwaves on male mating behaviour and reproductive success. We tested for the effects of heat stress induced by ecologically relevant heatwaves (33°C and 39°C for five consecutive days) on the mating behaviour, reproductive success, body mass and survival of male field crickets Gryllus bimaculatus, paired with untreated females. We predicted life-history and reproductive costs would increase with increasing heatwave intensity. Consistent with our expectations, males exposed to the highest heatwave temperature produced the fewest offspring, while having to increase courtship effort to successfully mate. Males also gained relatively more weight following heatwave exposure. Given that we found no difference in lifetime survival, our results suggest a potential trade-off in resource allocation between somatic maintenance and reproductive investment. Taken together, our findings indicate that sublethal effects of heatwaves could reduce the growth and persistence of animal populations by negatively impacting reproductive rates. These findings highlight the need for considering thermal ecologies, life history and behaviour to better understand the consequences of extreme climatic events on individuals and populations.
Participants will receive upadacitinib dose A daily in period 1. Eligible participants will receive upadacitinib dose B daily in period 2.
The objective of this study is to investigate the difference between the two riboflavin preparations during UV (ultraviolet) administration. Both riboflavin preparations currently are in general use worldwide and in U.S. clinical trials of corneal collagen crosslinking. The first preparation contains riboflavin in a dextran solution, which may tend to dehydrate the cornea and keep it thinner. The second preparation contains riboflavin in a solution without dextran; in this case, the relative hypotonicity may tend to keep the cornea better hydrated and thicker. The primary goal of the study is to see if the use of hypotonic riboflavin (rather than riboflavin with dextran) better maintains consistent corneal thickness during the CXL procedure. The second goal of the study is to determine if better maintenance of corneal thickness potentially could have benefits of better consistency of the procedure, decrease in corneal haze formation, and improved safety of the endothelial cells. Safety and efficacy outcomes will then be compared between the groups. In particular, we will compare the corneal thickness measured by ultrasonic pachymetry immediately after the CXL procedure in the randomized eyes. Secondary outcomes will include visual acuity, longer term corneal thickness changes, and corneal steepness changes. Safety assessments will include a tabulation of adverse events, patient symptoms, loss of visual acuity, changes in endothelial cell density, slit lamp examination of the cornea and lens, and contact lens tolerance for contact lens wearers
The present invention provides a radical generation catalyst capable of generating radicals under mild conditions.　This radical generation catalyst is characterized by comprising at least one selected from the group consisting of a compound represented by the following chemical formula (I), stereoisomers, tautomers, glycosides thereof, and salts thereof.　R 1 , R 3 , R 7  and R 9  are each a hydrogen atom or an alkyl group, or is absent. R 2 , R 6  and R 8  are each a hydrogen atom, an alkyl group, an amino group, a hydroxy group, an alkoxy group, an oxo group (=O ) or a thioxo group (=S), or is absent. H 2 , H 6 and H 8  are each a hydrogen atom, an alkyl group, an amino group, a hydroxy group or an alkoxy group, or is absent. L 1 , L 3 , L 7  and L 9  are each a single bond or is absent. L 2 , L 6  and L 8  are each a single bond or a double bond. L 11 , L 12 , L 13  and L 14  are each a single bond or a double bond.
Initiate intravenous infusions of FLOLAN at 2 ng/kg/min. Alter the infusion by 1- to 2-ng/kg/min increments at intervals sufficient to allow assessment of clinical response. These intervals should be at least 15 minutes.

During dose initiation, asymptomatic increases in pulmonary artery pressure coincident with increases in cardiac output may occur. In such cases, consider dose reduction, but such an increase does not imply that chronic treatment is contraindicated.

Base changes in the chronic infusion rate on persistence, recurrence, or worsening of the patient's symptoms of pulmonary hypertension and the occurrence of adverse vasodilatory reactions. In general, expect progressive increases in dose.

If dose-related adverse reactions occur, make dose decreases gradually in 2-ng/kg/min decrements every 15 minutes or longer until the dose-limiting effects resolve [see Adverse Reactions (6.1, 6.2)]. Avoid abrupt withdrawal of FLOLAN or sudden large reductions in infusion rates [see Warnings and Precautions (5.2)].

Following establishment of a new chronic infusion rate, measure standing and supine blood pressure for several hours.

Taper doses of FLOLAN after initiation of cardiopulmonary bypass in patients receiving lung transplants.
Chronic kidney disease (CKD) associated with type 2 diabetes (T2DM) is a global challenge; progression to end-stage kidney disease (ESKD) and increased risk of cardiovascular disease (CVD) associated with advancing nephropathy are a significant source of morbidity, mortality, and healthcare expenditure. Until recently, renin-angiotensin system (RAS) blockade was the mainstay of pharmacotherapy in diabetic kidney disease (DKD), representing a therapeutic paradigm shift towards interventions that delay disease progression independently of antihypertensive effects. However, a significant residual risk of DKD progression persisted in patients established on RAS blockade, highlighting the need for additional treatment options. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally licensed as glucose-lowering agents in people with T2DM, serendipitously demonstrated beneficial renal and cardiovascular outcomes in clinical trials designed primarily to evaluate their cardiovascular safety. The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial was the first to study the effect of SGLT2 inhibition on a primary composite renal endpoint of ESKD, doubling of serum creatinine, or renal or cardiovascular death in 4401 people with T2DM and CKD established on RAS blockade. The trial was stopped early due to efficacy, demonstrating a 30% relative risk reduction in the primary endpoint in the canagliflozin group (hazard ratio 0.70, 95% confidence interval 0.59-0.82; p = 0.00001). Through discussion of the primary analysis from CREDENCE, and selected post hoc analyses, we review the significant benefits highlighted by this landmark study, its role in shaping clinical guidelines, and in re-establishing interest in interventions that reduce the residual risk of progression of DKD, alongside its interrelation with cardiovascular morbidity and heart failure. We also provide a brief narrative summary of key renal outcome trials since CREDENCE, which indicate emerging avenues for pharmacotherapy beyond SGLT2 inhibition.
Aromatase inhibitor (AI) therapy is commonly used for treatment of postmenopausal women with hormone receptor-positive breast cancer. The most common toxicities are arthralgias and myalgias, which can be difficult to manage and necessitate discontinuation of therapy in up to 10% of patients. One potential interventional approach is with a pharmaceutical agent such as duloxetine, which has been shown to be effective for treatment of other types of chronic pain, including fibromyalgia and diabetic neuropathic pain.

The primary objective of this pilot study is to determine the proportion of breast cancer patients with AI-associated musculoskeletal symptoms who experience a 30% reduction in average pain score from baseline to 8 weeks due to duloxetine treatment. Participants will be treated with duloxetine for 8 weeks. Questionnaires to evaluate pain, functional status, depression, menopausal symptoms, and sleep difficulties will be administered at baseline and after 2, 4, 6, and 8 weeks of therapy. In addition, 10 milliliters blood of will be drawn from the subjects at baseline for future pharmacogenetic evaluation. If the results of this pilot study suggest that the efficacy of duloxetine therapy is greater than that expected from placebo based on historical controls, then these data will be used to design future prospective, placebo-controlled, randomized trials of treatment with duloxetine in this patient population.
Radiation causes damage to normal tissues that leads to increased oxidative stress, inflammation, and fibrosis, highlighting the need for the selective radioprotection of healthy tissues without hindering radiotherapy effectiveness in cancer. This study shows that adiponectin, an adipokine secreted by adipocytes, protects normal tissues from radiation damage invitro and invivo. Specifically, adiponectin (APN) reduces chronic oxidative stress and fibrosis in irradiated mice. Importantly, APN also conferred no protection from radiation to prostate cancer cells. Adipose tissue is the primary source of circulating endogenous adiponectin. However, this study shows that adipose tissue is sensitive to radiation exposure exhibiting morphological changes and persistent oxidative damage. In addition, radiation results in a significant and chronic reduction in blood APN levels from adipose tissue in mice and human prostate cancer patients exposed to pelvic irradiation. APN levels negatively correlated with bowel toxicity and overall toxicities associated with radiotherapy in prostate cancer patients. Thus, protecting, or modulating APN signaling may improve outcomes for prostate cancer patients undergoing radiotherapy.
The absorption and deposition of carotenoids added to poultry diets into the yolk of eggs produced by the poultry is improved by adding a carotenoid formulation comprising a carotenoid, a vegetable oil, a surfactant, a chelating agent, an antioxidant, an alkali and a solvent. The carotenoid formulation can reduce the crystalline nature of lutein for its better dissolution in the formulation and the diet. This new formulation is capable of making more micelles for an effective transfer of lutein from the formulations to the aqueous layer. The new formulation can increase the bioavailability of lutein in chicken biological system and leads to more deposition in the blood and the egg. The lutein deposition in the egg was consistent for an extended period of time when this new formulation was added to the diet. Addition of this carotenoid formulation to the diet increased the antioxidant power of the blood. Eggs produced by poultry fed diets supplemented by the formulation have in excess of 0.80 mg carotenoids per 100 grams of edible portion and thus serve as an important source of carotenoids in the human diet.
In Part A each subject will participate in six sessions and will be administered, in randomized order, single doses of five new formulations (formulation B, C, D, E and F) of SB-649868 30 milligrams (mg), in fasted state and a single dose of the original formulation (formulation A), after a standard Food and Drug Administration (FDA) High-Fat breakfast. All dosing sessions will be separated by a washout session of at least 5 ± 2 days after each dose. In Part B a single dose of the selected SB-649868 30 mg formulation will be administered after a standard FDA High-Fat breakfast.
The dosage and administering of margetuximab is 15 mg/kg IV every 21 days. Investigators need to choose one of the 3 chemotherapies based on patient conditions.
A composition for preventing and treating Alzheimer disease is provided to reduce accumulation of amyloid beta-protein lower saturated fatty acid without side effect. A composition for treating and preventing Alzheimer's disease comprises a monacolin isolated from red mold rice, anti-inflammation agent, antioxidant compound. The active minimum content of monacolin is 100mug per 1 g of red mold rice. The active minimum content of antioxidant compound is more than 40mug per 1g of red mold rice. The antioxidant compound is a dimerumic acid, tannin, phenol compound, monounsaturated fatty acid, sterols or superoxide dismutase(SOD). A method for manufacturing the composition for preventing and treating Alzheimer's disease comprises: a step of washing and sterilizing rice seed under the high pressure and high temperature; a step of culturing Monascus purpureus in medium; a step of stirring medium and providing moisture;; a step of stirring under the specific temperature and afterripening; a step of collecting fermented product of red mold rice and drying; a step of pulverizing the fermented product; and a step of resolving the fermented product in water.
The invention discloses a traditional Chinese medicine preparation used for treating recurrent oral ulceration. Recurrent oral ulceration belongs to disease category of aphtha and aphthous stomatitis in traditional Chinese medicine, and main clinical features are skin and mucosa ulcer impairments. Occurence of recurrent oral ulceration is always relates to emotional factors, liver Qi stasis is induced, fire transformation is caused by stasis, mouth is infected with fire, mucosa is damaged, and recurrent oral ulceration is caused by rotten and sore. The traditional Chinese medicine preparation is prepared by subjecting Rhizome of Chinese Tupistra, Herba Hedyotidis Corymbosae, tip of Licorice root, Michelia yunnanensis Franch. ex Finet et Gagnep, bamboo leaf, Ipomoea batatas, Anaphalis bicolor (Franch.) Diels, emblic leafflower, Semen sesami nigrum, and Cotinus coggygria to water decoction so as to obtain a decoction. It is confirmed by clinical experiment that total effective rate is 96%, and curative effect is excellent.
In Sevoflurane group, anaesthesia will be induced with Thiopental 5 - 7mg/kg, fentanyl citrate 2mcg/kg and atracurium besylate 0.5mg /kg to facilitate LMA placement. Anaesthesia will be maintained with sevoflurane 2-2.2 % to maintain a target MAC value between 0.8 \& 1.0.